DHEA bill returns
This article was originally published in The Tan Sheet
Executive Summary
Sen. Chuck Grassley, R-Iowa, on March 5 reintroduces a bill to list dehydroepiandrosterone as an anabolic steroid under the Controlled Substances Act. Co-sponsored by Sens. Dick Durbin, D-Ill. and John McCain, R-Ariz., S. 762 has been referred to the Judiciary Committee. In a same day release, Grassley says DHEA has "a number of potential long-term physical and psychological effects" including heart disease, cancer, stroke and liver damage. Industry groups maintain DHEA has little to no potential for abuse. Grassley previously introduced the measure in 2005 (1"The Tan Sheet" June 6, 2005, p. 11)...
You may also be interested in...
DHEA Debate Returns To Fore: Anabolic Steroid Status Sought In Grassley Bill
A new bill sponsored by Sen. Charles Grassley (R-Iowa) would regulate dehydroepiandrosterone (DHEA) as an anabolic steroid under the Controlled Substances Act
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.